Unidentified Analyst: Great. Thanks. We had another one on potentially use — I know you touched on potentially using combination therapies earlier, but could you elaborate on potential positioning in the current UC landscape given BT-600’s preliminary safety profile and how this might influence the target population for enrollment in a future Phase 1b?
Adi Mohanty: Okay. So, it’s a little tougher to talk about the combination therapy landscape. There are, as you know, some trials already happening where people are starting to try multiple molecules in these — in this patient population because here’s the core issue, right? Like almost all of these drugs end up working for 20% or 25% of the population and the remainder, like 2/3 don’t have anything. And so, people are trying these combinations. The biggest issue often holding people back is toxicity and toxicity with each individual drug. And then when you compound it with multiple drugs. So clearly, having a potentially lower toxic — toxicity or low level provides the opportunity to try multiple things along with BT-600.
So, we have had some preliminary conversations. But it’s a bit early to start telling you exactly what kind of combinations we can use. We do see the potential for BT-600 to move much sooner than where currently tofacitinib is in terms of where to use in second, third-line therapy. And so, the opportunity is going to be much larger as we go forward. We will know more. It’s a little early to tell you that. In terms of being acting the selection of the patients. I’ll let Ariella tell you a little bit about our current thinking of potentially what kind of patients we’re thinking about with Phase 1b, but that will evolve as we learn more from our MAD. Go ahead, Ariella.
Ariella Kelman: Yes. Thanks very much, Adi. So, we are planning a study in UC patients during the second half of 2024. And we should be able to provide more details in the coming months, but considering our goals for BT-600 which are higher colon tissue concentration which we know and data gross multiple treatments can be to greater indication and adjusted pathway as the site of disease and are associated with better efficacy in patient what do you see we think that first population I should be study artisans with moderate to severe ulcerative colitis, and that’s what we’re targeting for a UC trial.
Operator: Thank you. There are no further questions at this time. I’d like to hand the call back over to Adi Mohanty for any closing comments.
Adi Mohanty: Thank you all for joining us. We’re really excited with our progress and look forward to coming back and keeping everybody updated. Thank you.
Operator: Thank you all once again for joining us for the fourth quarter 2023 financial results call. We are excited about the progress — have a good evening, everyone. This completes our call.
